Karen Seiter, M.D. ’85, is a hematologist/medical oncologist who specializes in the treatment of patients with hematologic malignancies including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative diseases and lymphomas. She also has an interest in other diseases such as systemic mastocytosis and bone marrow failure syndromes. Dr. Seiter has been a member of the stem cell transplantation team at Westchester Medical Center for more than 30 years. In addition to her clinical chair of the New York Medical College Institutional Review Board, Oncology section, and is a member of the National Cancer Institute Central Institutional Review Board, Late Phase Emphasis Board.

Areas of Expertise

• Acute Leukemias
• Chronic Leukemias
• Myelodysplastic Syndrome
• Myeloproliferative Diseases
• Systemic Mastocytosis
• Bone Marrow Failure Syndromes
• General Hematology

Education

• M.D. '85, Medicine, New York Medical College
• Residency, Internal Medicine, Albert Einstein College of Medicine
• Fellowship, Hematology/Medical Oncology, Memorial Sloan-Kettering Cancer Center

Publications

• Borate U, Seiter K, Potluri R, et. al. "Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study." Advances in therapy, 41(11), (2024) 4049-4064. doi: 10.1007/s12325-024-02947-1
• Watts JM, Baer MR, Yang J, et. al. "Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial." The Lancet. Haematology, 10(1), (2023) e46-e58. doi: 10.1016/S2352-3026(22)00292-7
• Kantarjian HM, Begna KH, Altman JK, et. al. "Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)." Cancer, 127(23), (2021) 4421-4431. doi: 10.1002/cncr.33828
• Jacoby MA, Finn L, Emadi A, et. al. "Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)." Leukemia & lymphoma, 62(10), (2021) 2539-2542. doi: 10.1080/10428194.2021.1919668
• Yee K, Papayannidis C, Vey N, et. al. "Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆." Leukemia research, 100(), (2021) 106489. doi: 10.1016/j.leukres.2020.106489
• Aujla A, Hanmantgad M, Islam H, et. al. "Lineage switch from T-cell lymphoblastic leukemia/lymphoma to acute myeloid leukemia and back to T-cell lymphoblastic leukemia/lymphoma in a patient diagnosed during pregnancy." Stem cell investigation, 6(), (2019) 12. doi: 10.21037/sci.2019.05.02
• Knoll BM, Ahmed J, Karass M, et. al. "Procalcitonin as a biomarker to differentiate bacterial infections from engraftment syndrome following autologous hematopoietic stem cell transplantation for multiple myeloma." American journal of hematology, 94(3), (2019) E74-E76. doi: 10.1002/ajh.25378

View All Publications

Memberships and Affiliations

• American Society of Hematology
• American Society of Clinical Oncology
• American Association of Cancer Research
• Infectious Disease Society of America
• American Society of Gravitational and Space Research
• Environmental Mutagen Society
• American Association for the Advancement of Science
• American Astronomical Society